Hydrate Formation Patents: Top Companies & Filing Trends 2026
- 62.5% concentration. The top 5 of 79 ranked assignees hold 328 of 525 records in scope — over three-fifths of the field sits with a handful of oilfield chemical majors.
- +350% three-year climb. Filings rose from 2 in 2021 to 9 in 2024, even as the field's 2020 peak of 54 records has not been matched since.
- C09K dominates, C10G lags. 63.0% of records claim materials-for-applications formulations while only 6.5% touch hydrocarbon oil processing — the downstream handling side is comparatively open.
Filing growth compares 2021 (2 records) with 2024 (9) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 525 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
Hydrate formation prediction and prevention sits at the intersection of flow assurance chemistry and subsea production engineering. The 525 records in scope span thermodynamic and kinetic hydrate inhibitors, anti-agglomerants, methanol and monoethylene glycol (MEG) injection and regeneration systems, and hydrate blockage remediation methods. Coverage runs from 2015 through the 2026-07-31 cut-off, though publication lags filing by roughly 18 months, so the final one to two years understate true filing activity.
Filing offices concentrate around the United States, the WIPO PCT route and Europe, with meaningful volume also filed in Australia, Canada and Norway — a pattern consistent with offshore and subsea operators protecting inhibitor chemistry and deployment methods across the jurisdictions where deepwater and Arctic production actually occurs.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 525 records: how filing volume has moved year over year, and which IPC subclasses carry the claim density.
A 2020 peak, then a slow rebuild
Filings ran at 40 in 2017 and climbed to a peak of 54 in 2020 before falling back. From a 2021 low of 2, volume rebuilt to 9 by 2024 — a +350% move over that three-year span, though the count is still well below the 2020 peak. 2025 and 2026 figures are not yet complete because of publication lag and should not be read as a decline.
Claim density sits in materials and well chemistry
C09K (materials for miscellaneous applications) covers 63.0% of the 525 records, and C10L (fuels) and E21B (drilling/wells) follow at 35.6% and 32.0%. Downstream classes — C02F water treatment at 7.0% and C10G hydrocarbon oil processing at 6.5% — carry far less claim density, which is where formulation and process combinations remain comparatively unclaimed.
Shares are the percentage of the 525 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Hydrate Formation Prediction and Prevention with Eureka
This page is one run against one query. Ask Eureka your own question about hydrate formation prediction and prevention and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited prior art in this field
Regeneration of kinetic hydrate inhibitor
The present invention relates to a method and system for regeneration of kinetic hydrate inhibitor when it is used without a thermodynamic inhibitor. In that the use of a distillation column or tower is not needed, the present invention enables a more compact system, which also improves the possibility for heat integration of the regeneration process leading to very low energy consumption. Additional improvements over the prior art include reduced cost of buying new chemicals, reduced environmental impact because the chemicals are not discharged with the produced water and the possibility for the use of higher concentrations of kinetic hydrate inhibitor with still reduced cost and environmental impact.Filed by Statoil Petroleum AS, published 2014-11-27 — illustrates the shift toward regenerating kinetic inhibitors without a distillation tower.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US6025302A | Quaternized polyether amines as gas hydrate inhibitors | 104 |
| 2 | US20050081432A1 | Methods for inhibiting hydrate blockage in oil and gas pipelines using amide compounds | 73 |
| 3 | US20050261529A1 | Enhancement modifiers for gas hydrate inhibitors | 50 |
| 4 | US20100193194A1 | Method For Managing Hydrates In Subsea Production Line | 49 |
| 5 | US20060027369A1 | Additives for hydrate inhibition in fluids gelled with viscoelastic surfactants | 47 |
| 6 | WO2005042675A2 | Methods for inhibiting hydrate blockage in oil and gas pipelines using simple quaternary ammonium and phospho… | 47 |
| 7 | WO2009042319A1 | Method for managing hydrates in subsea production line | 44 |
| 8 | US20060223713A1 | Method of completing a well with hydrate inhibitors | 43 |
| 9 | US20160122619A1 | Cationic ammonium surfactants as low dosage hydrate inhibitors | 41 |
| 10 | US7381689B2 | Methods for inhibiting hydrate blockage in oil and gas pipelines using amide compounds | 40 |
Citation counts reflect influence within the searched corpus and skew toward older filings — treat them as a signal of foundational status, not current relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data means for filing strategy
Three findings that change where a freedom-to-operate search or a new filing should focus.
The field is chemistry-major territory
Five assignees hold 328 of the 525 records in scope. That concentration means core inhibitor chemistries — quaternary amines, amide-based blockers, enhancement modifiers — are heavily claimed by a small set of oilfield services and specialty chemical firms, and a new entrant's freedom-to-operate risk is dominated by watching those few portfolios rather than the long tail.
Activity is rebuilding, not peaking
After the 2020 peak of 54 records, filings dropped sharply, then recovered from 2 in 2021 to 9 in 2024. That is renewed interest, not a return to peak volume — and because 2025-2026 records are still arriving, the true current rate is higher than the chart shows.
Downstream handling is comparatively open
Materials-for-applications claims (C09K) cover 63.0% of the 525 records, while hydrocarbon oil processing (C10G) covers only 6.5%. Formulation chemistry is dense; process integration into refining and downstream handling is thinner ground for a new filing to test.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to hydrate formation prediction and prevention, with the prior art for and against each one.
Who is filing, and where the gaps sit
The ranked leaders and the sub-areas that remain thin, based on IPC-level claim density across the 525 records.
A single filer well ahead of the field
The leading assignee holds 114 records against a fifth-place figure of 28 and a tenth-place figure of 11 — a steep drop-off that marks this as a leader-plus-long-tail structure rather than an evenly split field.
Co-filing is limited and concentrated
Only 10 co-assignee pairs appear across the dataset, with the strongest pairing recorded at 17 shared records. Most filings are single-assignee, so joint development agreements are the exception rather than the norm in this field.
US, PCT and Europe anchor the filing map
The United States leads receiving offices with 131 records, followed by WIPO's PCT route at 78 and Europe at 54. Australia, Canada and Norway each carry secondary but non-trivial volume, tracking offshore and Arctic production geographies.
| Assignee | Recent year | YoY |
|---|---|---|
| Baker Hughes Holdings LLC | 0 | — |
| Ecolab USA Inc. | 0 | — |
| Clariant International Ltd. | 0 | — |
| HYDRAFACT | 0 | — |
| CHAMPIONX USA INC | 0 | — |
| Nalco Company | 0 | — |
| ExxonMobil Upstream Research Company | 0 | — |
| Huntsman Petrochemical LLC | 0 | — |
Where to take this analysis
The landscape points to specific next steps depending on whether the goal is defensive clearance or a new filing.
Run a freedom-to-operate check against the top 5
With 62.5% of records held by five assignees, a targeted FTO search against those portfolios covers most of the practical risk before a broader search is needed.
Explore assignee portfolios in EurekaTest claims in the under-claimed branches
MEG regeneration integration and subcooling margin instrumentation carry thinner claim density than core inhibitor chemistry — worth a novelty check before assuming the space is closed.
Run a white-space search in EurekaTrack the post-2024 filing rebuild
Filings rebuilt from 2 to 9 between 2021 and 2024; because of publication lag, the 2025-2026 figures will keep rising. Monitoring new publications as they land will surface the next wave of activity early.
Set up monitoring in EurekaCommon questions on hydrate formation patents
The ranked leader among 79 assignees holds 114 of the 525 records in scope, well ahead of the fifth-ranked assignee at 28 and the tenth at 11. That gap indicates a leader-plus-long-tail structure rather than a field split evenly among many players. The top 5 assignees combined account for 62.5% of all 525 records, so a competitive read of this space should start with those few portfolios rather than the full ranked list.
Filings peaked at 54 records in 2020, then fell sharply before rebuilding from 2 records in 2021 to 9 in 2024, a +350% increase over that span. The 2025 and 2026 figures look lower still, but that reflects publication lag of roughly 18 months rather than an actual slowdown — recent filings simply have not all published yet. Read the 2021-2024 rebuild as the more reliable current signal.
Thermodynamic inhibitors, historically methanol and MEG, shift the hydrate equilibrium curve and dominate older, highly-cited filings; kinetic hydrate inhibitors and anti-agglomerants delay or disperse hydrate crystal growth at lower dosing and appear across more recent formulation claims. The dataset's search terms cover both families together, and C09K (materials for miscellaneous applications) is the densest single IPC class at 63.0% of the 525 records, reflecting how much of this field is formulation chemistry rather than process engineering.
IPC-level claim density is markedly thinner in downstream classes: C10G (hydrocarbon oil processing) covers only 6.5% of the 525 records and C02F (water treatment) 7.0%, against 63.0% for core materials claims. Sub-areas such as MEG regeneration process integration, subcooling margin monitoring, and kinetic inhibitor regeneration without a distillation step show comparatively less claim density and are worth a targeted novelty search before assuming prior art blocks a new filing there.
The United States leads receiving offices with 131 of the tracked records, followed by the WIPO PCT route at 78 and the European Patent Office at 54. Australia, Canada and Norway each carry meaningful secondary volume, which lines up with where offshore, deepwater and Arctic production actually happens rather than with general patent filing volume by country.
Research Hydrate Formation Prediction and Prevention in depth with Eureka
Go past this page: query the whole hydrate formation prediction and prevention corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.